已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Level Ib sparing intensity-modulated radiation therapy in selected nasopharyngeal carcinoma patients based on the International Guideline

指南 鼻咽癌 病态的 医学 放射治疗 肿瘤科 外科 内科学 放射科 病理
作者
Qiaojuan Guo,Nan Xiao,Hanchuan Xu,Jingfeng Zong,Youping Xiao,Tianzhu Lu,Yun Xu,Bingyi Wang,Bijuan Chen,Jianji Pan,Shaojun Lin
出处
期刊:Radiotherapy and Oncology [Elsevier BV]
卷期号:167: 239-243 被引量:18
标识
DOI:10.1016/j.radonc.2021.12.032
摘要

Background and purpose To investigate the feasibility of level Ib sparing in selected nasopharyngeal carcinoma (NPC) patients during intensity-modulated radiation therapy (IMRT) based on the International Guideline. Patients and materials Patients with histologically-proven NPC who received definitive IMRT at our group were candidates for this analysis. Other eligibility criteria for analysis were designed according to the recommendation of International Guideline for selective coverage of level Ib. Survival outcomes focused on regional recurrence-free survival (RRFS) and level Ib recurrence rate were analyzed. Results A total of 450 patients were included, 60 of them received level Ib-covering IMRT due to the first three principles of the International Guideline according to our protocol. Of note, patients with level Ib involvement would receive ultrasound guided puncture, only those with positive pathological results would undergo level Ib-covering IMRT. For the remaining 390 patients who only fulfilled the last two criteria and/or level Ib involvement with negative pathological results, level Ib-sparing IMRT was delivered, with a median follow-up time of 112 months (range 6 to 194 months), reported 5- and 10-year RRFS were 95.4% and 92.9%, respectively. Twenty-two patients occurred regional recurrence at censorship (median 44.5 months), only 4(4/390, 1.03%) were recorded as level Ib recurrence. Conclusion Level Ib-sparing IMRT should be safe and feasible for patients who only had level II involvement with ECE, and/or had a MAD of greater than 2 cm in level II, and/or level Ib involvement with negative pathological results. Further well-designed multi-center prospective trials should be conducted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
leegawei发布了新的文献求助10
刚刚
13054567414发布了新的文献求助10
1秒前
1秒前
彭于晏的应助被011采纳,获得10
2秒前
2秒前
jnzdb02完成签到 ,获得积分10
5秒前
挚友发布了新的文献求助10
5秒前
能干的惜珊完成签到,获得积分10
6秒前
jacob258完成签到 ,获得积分10
6秒前
6秒前
xiaoxiao发布了新的文献求助10
7秒前
认真的狗发布了新的文献求助10
7秒前
艾托斯克完成签到,获得积分10
7秒前
ppp发布了新的文献求助10
8秒前
尹依依完成签到 ,获得积分10
11秒前
丁爽发布了新的文献求助10
12秒前
Jun的应助被科研通管家采纳,获得20
14秒前
Jun的应助被科研通管家采纳,获得20
14秒前
FashionBoy的应助被科研通管家采纳,获得10
14秒前
1111发布了新的文献求助10
14秒前
Jun的应助被科研通管家采纳,获得20
14秒前
完美世界的应助被科研通管家采纳,获得30
14秒前
14秒前
小马甲的应助被科研通管家采纳,获得10
14秒前
1aswd2完成签到,获得积分10
14秒前
xjz完成签到 ,获得积分10
15秒前
顾矜的应助被合适的咖啡采纳,获得10
16秒前
17秒前
不想接受完成签到 ,获得积分10
17秒前
欢喜的毛巾完成签到,获得积分10
18秒前
011发布了新的文献求助10
18秒前
木子李完成签到 ,获得积分10
19秒前
节步青发布了新的文献求助30
20秒前
hhzzhhggff完成签到 ,获得积分10
20秒前
夏凉完成签到 ,获得积分10
21秒前
情怀的应助被负责的书易采纳,获得10
23秒前
23秒前
23秒前
24秒前
科研通AI6.4的应助被丁爽采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165576
求助须知:如何正确求助?哪些是违规求助? 9559107
关于积分的说明 21748964
捐赠科研通 7756283
什么是DOI,文献DOI怎么找? 3428926
关于科研通互助平台的介绍 2553233
邀请新用户注册赠送积分活动 2473520